by blood component transfusion A linked donor-recipient study to evaluate parvovirus B19 transmission
暂无分享,去创建一个
S. Glynn | S. Kleinman | M. Busch | L. Tobler | K. Schlumpf | Tzong-Hae Lee | Mei-ying W. Yu | D. Todd | Hannah Qiao | M. Yu
[1] M. Busch,et al. Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion , 2009, Transfusion.
[2] Y. Tani,et al. Persistent infection by human parvovirus B19 in qualified blood donors , 2008, Transfusion.
[3] P. Simmonds,et al. Parvoviruses and blood transfusion , 2007, Transfusion.
[4] S. Glynn,et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay , 2007, Transfusion.
[5] E. Seifried,et al. Blood donor screening for parvovirus B19 in Germany and Austria , 2007, Transfusion.
[6] A. Parsyan,et al. Human erythrovirus B19 and blood transfusion – an update , 2007, Transfusion medicine.
[7] Y. Geng,et al. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing , 2007, Transfusion.
[8] A. Parsyan,et al. Effects of transfusion on human erythrovirus B19‐susceptible or ‐infected pediatric recipients in a genotype 3–endemic area , 2006, Transfusion.
[9] S. Doyle,et al. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. , 2006, The Journal of infectious diseases.
[10] E. Holler,et al. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products , 2005, Transfusion.
[11] J. Lefrère,et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. , 2005, Blood.
[12] Nitin R. Patel,et al. Exact Inference for Categorical Data , 2005 .
[13] C. Nass,et al. The RADAR repository: a resource for studies of infectious agents and their transmissibility by transfusion , 2005, Transfusion.
[14] B. Evatt,et al. Parvovirus B19 transmission by a high‐purity factor VIII concentrate , 2005, Transfusion.
[15] A. Parsyan,et al. Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor Samples , 2004, Journal of Virology.
[16] S. Doyle,et al. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. , 2004, Journal of medical microbiology.
[17] M. Di Giambattista,et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non‐structural viral proteins , 2003, Vox sanguinis.
[18] J. Löwer,et al. Parvovirus B19 transmission by heat‐treated clotting factor concentrates , 2002, Transfusion.
[19] W. Hitzler,et al. Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction , 2002, Vox sanguinis.
[20] N. Young,et al. Parvovirus B19: implications for transfusion medicine. Summary of a workshop , 2001, Transfusion.
[21] T. Eastlund,et al. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasma , 2000, Transfusion.
[22] J. Kiss,et al. Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients , 1998, Vox Sanguinis.
[23] M. Ferguson,et al. Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. , 1997, Biologicals (Print).
[24] J. Goldman,et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion , 1997, Transfusion.
[25] M. Morfini,et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization , 1997 .
[26] Y. Yoto,et al. Incidence of human parvovirus B19 DNA detection in blood donors , 1995, British journal of haematology.
[27] A. Zanella,et al. Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patient , 1995, Transfusion.
[28] N. Young,et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). , 1994, The New England journal of medicine.
[29] P. Mannucci,et al. Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates , 1992, American journal of hematology.
[30] N. Young. Hematologic and hematopoietic consequences of B19 parvovirus infection. , 1988, Seminars in hematology.
[31] P. Mortimer,et al. TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATES , 1983, The Lancet.